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ABSTRACT   Although the prognosis of differentiated thyroid cancer (DTC) is good, those of 
poorly-differentiated and undifferentiated thyroid cancers (PDTC and UDTC) are poor. Recent 
preclinical studies have suggested that the Src inhibitor dasatinib is active in thyroid cancer 
cell lines. We conducted the present study in an attempt to clarify the antitumor activity of 
dasatinib in PDTC and UDTC.
   The expression levels of c-Src, phosphorylated Srcs (p-SrcY416 and p-SrcY527), focal 
adhesion kinase (FAK), and phosphorylated FAK (p-FAKY861) were immunohistochemically 
investigated in a case-control series (15 cases of PDTC or UDTC vs. 29 control cases of 
DTC). The PDTC cell line KTC-1 and UDTC cell line KTC-2 were used to investigate the anti-
cell growth and anti-cancer stem cell (CSC) activities of dasatinib. The combined effects 
of dasatinib and the taxane paclitaxel on anti-cell growth and anti-CSC activities were also 
tested.
   c-Src and p-FAKY861 expression levels were significantly higher, while those of p-SrcY416 
were slightly higher in PDTC and UDTC than in DTC. Dasatinib inhibited cell growth in 
association with G1-S cell cycle retardation and increased apoptosis in both cell lines. 
Dasatinib significantly decreased the proportion of CSCs and more than additively enhanced 
the anti-cell growth activity of paclitaxel.
   The results of this study suggest that the Src signaling pathway is activated more in PDTC 
and UDTC than in DTC. The Src inhibitor dasatinib exhibited anti-cell growth and anti-
CSC activities. Furthermore, it more than additively enhanced the anti-cell growth activity of 
paclitaxel. doi：10.11482/KMJ-E43（2）63　(Accepted on June 19, 2017)
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INTRODUCTION
   Differentiated thyroid cancer (DTC) is the most 
common type of thyroid cancer, and surgical 
therapy with or without radioactive iodine (RAI) 
provides patients with an excellent prognosis. 
However, poorly-differentiated and undifferentiated 
thyroid cancers (PDTC and UDTC) have very 
aggressive biological and clinical behaviors and are 
resistant to radioactive iodine. Patients with these 
aggressive tumors have poor outcomes. Therefore, 
the development of new molecular targeting agents 
is urgently needed for the control of such incurable 
thyroid cancers１）.
   In recent years, several tyrosine kinase inhibitors 
(TKIs) have been investigated for the treatment 
of advanced RAI-resistant thyroid cancers, and 
some have recently been approved for clinical use: 
sorafenib and lenvatinib for DTC and PDTC and 
vandetanib and cabozantinib for medullary thyroid 
cancers２）. Lenvatinib has also been used in the 
treatment of patients with UDTC in Japan due to 
its favorable efficacy in UDTC patients in a clinical 
trial conducted in Japan３）. However, the clinical 
usefulness of the single administration of these 
TKIs is limited. More potent TKIs or more active 
combination therapies with chemotherapeutic agents 
are needed in order to achieve a more favorable 
impact in patients with aggressive thyroid cancers. 
   Recent preclinical studies have suggested that 
Src family kinases (SKFs) are activated in thyroid 
cancer cells and the Src inhibitor dasatinib has 
been shown to suppress their growth and metastasis 
in various thyroid cancer cell lines including 
UDTC４－９）. Therefore, we conducted the present 
study in an attempt to clarify these findings, 
particularly the antitumor activity of dasatinib in 
PDTC and UDTC.
   Tumor-initiating cells or cancer stem cells (CSCs) 
have been suggested to exist in solid tumors 
including thyroid cancers. CSCs may also play 
important roles in cancer initiation, progression, 
recurrence, metastasis, and resistance to anticancer 
agents and radiotherapy. If an anticancer agent 
exhibits anti-CSC activity as well as anti-cell growth 
activity, it may provide cancer patients with longer 
progression-free survival or a cure10）. Therefore, we 
also investigated the anti-CSC effects of dasatinib in 
PDTC and UDTC cells.
   Recent clinical studies have suggested that the 
taxane paclitaxel is active in patients with advanced 
DTC or UDTC11，12）. In order to examine the 
hypothesis that dasatinib may enhance the antitumor 
activity of paclitaxel, the combined effects of 
dasatinib and paclitaxel on anti-cell growth and anti-
CSC activities were also tested in this study.
MATERIALS AND METHODS
Immunohistochemical analysis of Src and focal 
adhesion kinase (FAK) pathways
   A case-control study using formalin-fixed paraffin-
embedded thyroid cancer samples was conducted in 
order to compare the expression levels of molecules 
related to the Src and FAK pathways in PDTC 
and UDTC with those in DTC. Fifteen patients 
with PDTC or UDTC were randomly selected 
as cases from thyroid cancer patients treated at 
the Department of Breast and Thyroid Surgery, 
Kawasaki Medical School between 1983 and 2003, 
and 29 patients with DTC were selected as gender- 
and age-matched controls. This study protocol was 
approved by the Ethical Committee of Kawasaki 
Medical School (approval number: 2310).
   Five-micrometer-thick paraffin sections were 
dewaxed with xylene and hydrated. Antigen retrieval 
was performed in a 95℃ water bath for 40 min in 
Target Retrieval Solution (pH 9.0; Dako, Glostrup, 
Denmark) for c-Src, p-SrcY416, p-SrcY527, and 
FAK or in citrate buffer at pH 6.0 for p-FAKY861. 
Endogenous peroxidase activity was blocked by an 
incubation in 3% hydrogen peroxide for 5 min. The 
primary antibodies used were: c-Src (Src antibody, 
polyclonal, 1:800, Cell Signaling Technology, 
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Danvers, MA, USA), p-SrcY416 (phosphorylated 
Src family Tyr416 antibody, polyclonal, 1:100; Cell 
Signaling Technology), p-SrcY527 (phosphorylated 
Src family Tyr527 antibody; polyclonal, 1:50; 
Cell Signaling Technology), FAK (FAK antibody, 
polyclonal, 1:400, Cell Signaling Technology), and 
p-FAKY861 (phosphorylated FAK Tyr861 antibody, 
polyclonal, 1:400; Invitrogen, Camarillo, CA, USA). 
After an overnight or one-hour incubation, slides 
were washed in Tris-buffered saline, and EnVision+ 
(Dako) was then applied. The chromogen used was 
diaminobenzidine. Sections were counterstained 
with hematoxylin and mounted. Samples in which 
the primary antibody was omitted served as negative 
controls13，14）.
   Protein expression levels in thyroid cancer cells 
were assessed over the full tissue specimen using 
the histoscore method. Staining intensity was graded 
as negative (0), weak (1), moderate (2), and strong 
(3). The histoscore was calculated by multiplying 
the percentage of positively-stained tumor cells by 
the intensity. One pathologist (NK) scored all tissue 
sections in a blinded manner.
   In order to investigate the expression levels of 
c-Src and phosphorylated Srcs in thyroid cancer cell 
lines, harvested cells were washed once with cold 
phosphate-buffered saline (PBS) and centrifuged 
at room temperature. The cell pellet was fixed with 
10% phosphate-buffered formalin overnight and 
embedded in paraffin15）. An immunohistochemical 
analysis was performed as described above.
Western blot analysis
   Cells were lysed for protein extraction using Pierce 
RIPA Buffer with protease inhibitor and phosphatase 
inhibitor (Thermo Fisher Scientific, Waltham, 
MA, USA). The total protein concentration was 
measured using the Pierce BCA Protein Assay kit 
(Thermo Fisher Scientific). Isolated proteins were 
separated by 5-20% SDS-PAGE and transferred to 
an Immobilon-FL (Merck Millipore Corporation, 
Billerica, MA, USA). Membranes were blocked 
with blocking buffer (5% BSA in 1 x Tris buffer 
saline with 0.1% Tween 20) at room temperature for 
one hour, subjected to immunoblots using primary 
antibodies at 4℃ overnight, and then incubated 
with secondary antibodies at room temperature 
for one hour. Labeled protein was visualized using 
ECL Prime Western Blotting Detection Reagent 
(GE Healthcare Japan) with the expression of 
β-actin as the internal standard. Rabbit monoclonal 
antibodies against Src, β-actin, p-SrcY416, and 
FAK were from Cell Signaling Technologies. A 
polyclonal antibody to p-FAKY861 was purchased 
from Thermo Fisher  Scient ific .  Secondary 
antibodies, goat anti-rabbit lgG-HRP, and goat anti-
mouse lgG-HRP were purchased from Santa Cruz 
Biotechnology (Dallas, Texas, USA). Specific bands 
were visualized using LAS-1000 UVmini (GE 
Healthcare, Tokyo, Japan) and analyzed for density 
using Quantity One 1-D analysis software, ver. 4.5 
(BIORAD, Tokyo, Japan).
Reagents
   Dasatinib was purchased from CHEMSCENE, 
LLC (Monmouth Junction, NJ, USA). Paclitaxel 
was purchased from Sigma Co. (St Louis, MI, 
USA).
Thyroid cancer cell lines and culture conditions
   The poorly-differentiated papillary thyroid cancer 
cell line KTC-1 and UDTC cell line KTC-2 were 
established in our laboratory16，17）. Both cell lines 
were routinely maintained in RPMI1640 medium 
supplemented with 10% fetal bovine serum (FBS).
   According to the findings of a comprehensive 
study conducted by Schweppe RE et al., KTC-1 
and KTC-2 were both proven to be unique thyroid 
cancer cell lines18）. In all in vitro experiments 
performed in the present study, earlier passages 
(around the 30th passage) of either KTC-1 or KTC-2 
cells were used.
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Cell growth analysis
   In order to investigate the effects of dasatinib 
and/or paclitaxel on cell growth, KTC-1 or KTC-
2 thyroid cancer cells (1 - 5 × 104 cells per well) 
were seeded on 24-well plates (SB Medical, 
Tokyo, Japan) and grown in RPMI1640 medium 
supplemented with 10% FBS at 37℃ in a 5% CO2 
atmosphere for two days. After washing with PBS, 
cells were incubated with RPMI1640 medium 
supplemented with 10% FBS plus the indicated 
concentrations of dasatinib and/or paclitaxel. In the 
paclitaxel treatment, cells were exposed to paclitaxel 
for 4 hours, washed with PBS, and cultured with 
fresh medium without paclitaxel thereafter for 
three days. In the dasatinib treatment, cells were 
continuously exposed to dasatinib for three days. 
After the incubation, cells were harvested and 
counted with a Coulter counter (Coulter Electronics, 
Harpenden, UK). Reproducibility was confirmed in 
at least two separate experiments. 
   In order to evaluate the antitumor effects of the 
combined treatments, a combination index based 
on the 50% inhibitory concentration (IC50) was 
calculated according to the following formula: 
combination index = IC50 with the combined 
treatment/IC50 with the single treatment.  A 
combination index < 0.5 was considered to be 
evidence of a more than additive interaction19）.
Cell cycle and apoptosis analyses
   In order to investigate the effects of agents on the 
cell cycle and apoptosis, approximately 5 × 105 
cells per well were plated into T-25 flasks (Corning 
Japan, Tokyo, Japan) and cultured in RPMI1640 
medium supplemented with 10% FBS for two days. 
Cells were then washed twice with PBS and cultured 
for two days in RPMI1640 medium supplemented 
with 10% FBS plus the indicated concentrations of 
dasatinib and/or paclitaxel. Duplicate flasks were 
trypsinized and harvested.
   In order to investigate the effects of agents on 
cell cycle progression, harvested cells were stained 
with propidium iodide using a CycleTest Plus 
DNA Reagent kit (Becton Dickinson, San Jose, 
CA, USA). Flow cytometry was performed with a 
FACSCalibur flow cytometer (Becton Dickinson), 
and the DNA histogram obtained was analyzed 
using CELLQuest version 1.2.2 (Becton Dickinson). 
The percentages of apoptotic cells were measured 
by FACSCalibur flow cytometry (Becton Dickinson) 
using an Annexin-V-FLUOS staining kit (Roche 
Diagnostics GmbH, Penzberg, Germany) according 
to the manufacturer’s recommendations.
Aldefluor assay
   In order to investigate the effects of agents on 
putative thyroid CSCs, the ALDEFLUOR kit 
(StemCell Technologies, Durham, NC, USA) was 
used to isolate the population exhibiting strong 
aldehyde dehydrogenase (ALDH) enzymatic 
activity. Harvested cells were suspended in 
Aldefluor assay buffer containing ALDH substrate 
(BODIP-aminoacetaldehyde, 1 μmol/l per 1 × 
106 cells) and incubated at room temperature for 40 
minutes. As a negative control, cells were treated 
with 50 mmol/l diethylaminobenzaldehyde (DEAB), 
a specific ALDH inhibitor20）.
Thyrosphere assay
   In order to investigate the effects of agents on 
putative thyroid CSCs, KTC-1 or KTC-2 thyroid 
cancer cells (approximately 1.5 x 105 cells per 
well) were seeded on 35-mm dishes (SB Medical) 
and grown in RPMI1640 medium supplemented 
with 10 % FBS at 37℃ in a 5 % CO2 atmosphere 
for two days. After washing with PBS, cells were 
treated with RPMI1640 medium supplemented 
with the indicated concentrations of dasatinib and/
or paclitaxel. After washing with PBS, cells were 
incubated with RPMI1640 medium supplemented 
with 10% FBS plus the indicated concentrations 
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of dasatinib and/or paclitaxel. In the paclitaxel 
treatment, cells were exposed to paclitaxel for 4 
hours, washed with PBS, and cultured with fresh 
medium without paclitaxel thereafter for three days. 
In the dasatinib treatment, cells were continuously 
exposed to dasatinib for three days. These cells 
were then dispersed, and single-cell suspensions (5 
x 103 cells/well) were incubated in MammoCultTM 
basal medium (STEMCELL Technologies Co., 
Vancouver, Canada) supplemented with 10% 
MammoCultTM prol i fera t ion supplements 
(STEMCELL Technologies Co.) in non-adhesive 
6-well plates (CORNING Co., NY, USA) for seven 
days. Thyrospheres larger than 60 μm were counted 
with an Olympus phase-contrast microscope20）.
Statistical analysis
   All values are expressed as the mean ± SE. An 
ANOVA analysis with StatView computer software 
(ATMS Co., Tokyo, Japan) was used to compare 
differences between two groups. A two-sided P 
value less than 0.05 was considered significant.
RESULTS
Immunohistochemical analysis
   No significant differences were observed in 
gender or age between the PDTC/UDTC group and 
DTC group (Numbers of male and female patients: 
7 and 8, 12 and 17, median age of patients: 67 years 
old, 66 years old, respectively). Only two cases were 
diagnosed as PDTC in the PDTC/UDTC group. No 
variant types of DTCs were included in the DTC 
group.
   The expression levels of molecules related to the 
Src and FAK pathways in thyroid cancer cells were 
immunohistochemically evaluated in these thyroid 
cancer samples using the histoscore system. The 
expression levels of c-Src and p-FAKY861 were 
significantly higher in the PDTC/UDTC group 
than in the DTC group (P = 0.001 and P = 0.0008, 
respectively, Fig. 1A, E). Similarly, the expression 
levels of p-SrcY416 and p-SrcY527 tended to be 
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Fig. 1  Immunohistochemical analysis of c-Src, p-SrcY416, p-SrcY527, FAK, and p-FAKY861 expression levels in 
thyroid cancer samples. Samples were divided into two groups, the PDTC/UDTC group and DTC group. They were 
immunostained and evaluated using the histoscore system as described in the Materials and Methods. Values are 
expressed as means ± SEs. *, P < 0.05; **, P < 0.01 significant difference between the two groups.
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higher in the PDTC/UDTC group (P = 0.0506 and 
P = 0.1702, respectively, Fig. 1B, C). In contrast, 
the expression levels of FAK were markedly lower 
in the PDTC/UDTC group than in the DTC group 
(P < 0.0001, Fig. 1D). These results suggest that 
the baseline expression level of c-Src and also 
the expression level of an activated form of c-Src, 
p-SrcY416 appeared to be higher in PDTC and 
UDTC than in DTC. Additionally, a downstream 
molecule for Src signaling, FAK was strongly 
activated in PDTC and UDTC. Representative 
microphotographs for the immunohistochemical 
analysis are shown in Fig. 2. 
Inhibitory activity of dasatinib on Src and FAK 
signaling
   Based on the results of immunocytochemical 
and Western blot analyses, dasatinib (10 or 100 
nM) dose-dependently decreased the expression of 
p-SrcY416 and p-FAKY861, but not that of c-Src or 
FAK in the KTC-1 and KTC-2 cell lines (Figs. 3A, 
B, and 4A-F).
Anti-cell growth activity of dasatinib
   Dasatinib dose-dependently inhibited cell growth 
in the KTC-1 and KTC-2 cell lines (Fig. 5A). IC50s 
were 11.64 ± 4.85 nM and 18.91 ± 4.94 nM, 
respectively. Based on our previous study using 
breast cancer cell lines, IC50s ranged between 
100 nM and 5,000 nM under similar culture 
conditions13）. These findings suggest that the two 
thyroid cancer cell lines used in the present study 
are very sensitive to dasatinib.
   In order to elucidate the mechanisms responsible 
for the anti-cell growth activity of dasatinib, its 
effects on cell cycle progression and apoptosis 
were investigated. Dasatinib dose-dependently 
increased the cell population at the G1 phase and 
decreased that at the S phase, i.e., induced G1-S 
cell cycle retardation in both cell lines (Fig. 5B, D). 
Furthermore, dasatinib dose-dependently increased 
the cell population at the sub-G1 phase, and also 
increased apoptotic fractions measured by the 
Annexin V assay in both cell lines (Fig. 5B-E).
Anti-CSC activity of dasatinib
   Dasatinib dose-dependently decreased putative 
CSC populations, ALDH-positive cell populations 
measured by the Aldefluor  assay,  and cel l 
populations building thyrospheres measured by 
the thyrosphere assay in KTC-1 cells (Fig. 6A, C). 
Similarly, dasatinib dose-dependently decreased 
the proportion of ALDH-positive cells and number 
of thyrospheres in KTC-2 cells (Fig. 6E, F). In 
addition, representative results of the Aldefluor 
assay (Fig. 6B) and thyrosphere assay (Fig. 6D) in 
KTC-1 cells treated with dasatinib are shown.
Figure 2
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Fig. 2  Representative immunostaining for c-Src, p-SrcY416, p-SrcY527, FAK, and p-FAKY861 as well as H-E staining as 
controls in DTC and UDTC tissue samples. The original magnification was x 20.
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Figure 3
A
B
Fig. 3  Immunocytochemical analysis of the effect of dasatinib on c-Src, p-SrcY416, and p-SrcY527 
expression levels in KTC-1 cells (A) and KTC-2 cells (B).
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Fig. 4  Western blot analysis of effects of dasatinib (10 or 100nM) on c-Src, p-SrcY416, FAK and p-FAKY861 expression levels 
in KTC-1 cells (A) and KTC-2 cells (C). Band intensities for p-SrcY416 (B, D) and p-FAKY861 (C, E) were analyzed in KTC-1 
and KTC-2 cells, respectively.  and of dasatinib (10, 50 or 100nM) on pan-FAK and p-FAKY861 expression levels in KTC-1 cells 
(B) and KTC-2 cells (D). Values are expressed as means ± SEs of control. *, P < 0.05 significantly different from the control.
Fig. 5  Effects of dasatinib on growth (A: closed circles for KTC-1 and open circles for KTC-2), cell cycle progression (B for 
KTC-1 and D for KTC-2), and apoptosis (C for KTC-1 and E for KTC-2) in thyroid cancer cells. Both cell lines were treated with 
10 or 100 nM dasatinib for three days in the cell growth assay or two days in the cell cycle and apoptosis assays as described in 
the Materials and Methods. Values are expressed as means ± SEs of % control. The white bars denote as control values, grey 
bars as 10 nM dasatinib-treated, and black bars as 100 nM dasatinib-treated. *, P < 0.05; **, P < 0.01 significantly different from 
the control.
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Fig. 6  Effects of dasatinib on the proportion of ALDH-positive cells and number of thyrospheres/1,000 cells seeded in KTC-
1 cells (A, C) and KTC-2 cells (D, F). Cells were treated with dasatinib for three days. The percentage of ALDH-positive cells 
and number of thyrospheres were measured as described in the Materials and Methods. Values are expressed as means ± SEs. 
White bars, control; light grey bars, 10 nM dasatinib-treated; dark grey bars, 100 nM dasatinib-treated. * P < 0.05; **P < 0.01 
significantly different from control cells. Representative results of the Aldefluor assay (B) and thyrosphere assay (E) in KTC-1 
cells treated with dasatinib are also shown. The dots in the R3 area were ALDH-positive cells (B).
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Combined antitumor effects of dasatinib and 
paclitaxel
   Combined treatments of dasatinib and paclitaxel 
more than additively inhibited cell growth in both 
cell lines (Fig. 7A, B). Combination indexes at IC50 
for paclitaxel were 0.03±0.00 (n = 2) for KTC-1 
cells and 0.10±0.03 (n = 2) for KTC-2 cells.
   In order to elucidate the mechanisms responsible 
for the effects of the combination treatments, 
the combined effects of the agents on cell cycle 
progression and apoptosis were investigated. 
Dasatinib significantly enhanced increases in 
apoptotic fractions induced by paclitaxel, but not 
G1-S cell cycle retardation in both cell lines (Fig. 
8A-D).
Combined anti-CSC effects of dasatinib and 
paclitaxel
   Paclitaxel alone modestly decreased the putative 
CSC population and number of thyrospheres/1000 
cells seeded measured by the thyrosphere assay in 
KTC-1 cells, but not in KTC-2 cells (Fig. 9A-D). 
The combined treatment of dasatinib and paclitaxel 
enhanced the decrease in the CSC population 
induced by paclitaxel in KTC-1 cells (Fig. 9B).
DISCUSSION
   SFKs play important roles in cell survival, 
proliferation, adhesion, invasion, and angiogenesis 
during cancer development. SFKs comprise at least 
nine family members that share similar structures 
and functions. The overexpression and/or activation 
of SFKs are frequently observed in cancer tissues. 
These findings suggest that SFKs are promising 
targets for cancer therapeutics. A number of 
preclinical studies revealed that small-molecule SFK 
inhibitors exert potent antitumor and anti-metastatic 
effects in various cancer models, some of which are 
under early phase clinical trials21）.
   Dasatinib is a potent inhibitor of multiple tyrosine 
kinases including BCR-ABL, c-KIT, platelet-
derived growth factor receptor, and SFKs. It has 
been mainly used in the treatment of patients 
with chronic myeloid leukemia and Philadelphia 
chromosome-positive acute lymphoblastic leukemia. 
However, the antitumor effects of dasatinib have 
also been examined in a wide variety of solid tumors 
in clinical trials as a potent inhibitor of SFKs22，23）. 
Positive findings have been reported for patients 
with breast or ovarian cancer24－27）.
   Regarding thyroid cancer, a few studies have 
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Fig. 7  Growth inhibitory curves of combined treatments of dasatinib and paclitaxel in KTC-1 cells (A) and KTC-2 cells (B). 
Cells were treated with or without 10 nM dasatinib plus the indicated concentrations of paclitaxel for three days. Values are 
expressed as means ± SEs. Open circles, paclitaxel alone-treated; closed circles, paclitaxel plus 10 nM dasatinib-treated.
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Fig. 8  Effects of combined treatments of dasatinib and paclitaxel on cell cycle progression and apoptosis in KTC-1 cells (A, 
B) and KTC-2 cells (C, D). Cells were treated with or without 10 nM dasatinib and paclitaxel (2.5 or 5 nM) for two days. 
The percentages of cells at each cell cycle phase were analyzed as described in the Materials and Methods. The percentage of 
apoptotic cells was analyzed as described in the Materials and Methods. Values are expressed as means ± SEs. White bars, 
control; the lightest gray bars, dasatinib alone; the second lightest gray bars, paclitaxel alone; and the darkest gray bars, dasatinib 
plus paclitaxel. * P < 0.05; **P < 0.01 significantly different from control cells.
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Fig. 9  Effects of dasatinib and paclitaxel on the proportion of ALDH-positive cells and number of thyrospheres/1,000 cells 
seeded in KTC-1 cells (A, B) and KTC-2 cells (C, D). Cells were treated with or without 10 nM dasatinib and paclitaxel (2.5 
or 5 nM) for two days. The percentage of ALDH-positive cells and number of thyrospheres were measured as described in the 
Materials and Methods. Values are expressed as means ± SEs. White bars, control; the lightest gray bars, dasatinib alone; the 
second lightest gray bars, paclitaxel alone; and the darkest gray bars, dasatinib plus paclitaxel. * P < 0.05; **P < 0.01 significantly 
different from control cells.
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measured the expression levels of SFKs in 
thyroid cancer tissues. Michailidi C et al. reported 
that the expression levels of total Src and FAK 
were significantly higher in papillary thyroid 
cancer than in benign thyroid nodules in an 
immunohistochemical study. They also suggested 
that total Src expression levels correlated with tumor 
size, while total FAK expression levels correlated 
with capsular and lymphatic invasion in thyroid 
cancers28）. Cho NL et al. conducted global tyrosine 
kinome profiling for papillary thyroid cancer tissues 
and showed that phosphorylated Src expression 
was up-regulated and correlated with invasion29）. 
Schweppe RE et al. reported that FAK, a critical 
substrate and effector of Src, was phosphorylated 
at tyrosine residue 861 in most papillary thyroid 
cancers in an immunohistochemical study14）. These 
findings prompted us to investigate the expression 
levels of c-Src, phosphorylated Src, FAK, and 
phosphorylated FAK using immunohistochemistry 
in the present study.
   Since PDTC and UDTC are relatively rare 
diseases, an immunohistochemical study using a 
case-control method (PDTC/UDTC as the case 
and DTC as the control) with gender and age 
matching was conducted in this study. The results 
of the present study suggest for the first time that 
the expression levels of c-Src, phosphorylated Src, 
and phosphorylated FAK were significantly higher 
in PDTC/UDTC than in DTC. In contrast, FAK 
expression was significantly lower in PDTC/UDTC 
than in DTC (Figs. 1, 2). FAK expression has been 
suggested to correlate with malignant progression 
in thyroid tumors28）. De-differentiation from DTC 
to PDTC/UDTC may decrease FAK expression 
levels in spite of the accelerated activation of FAK. 
Further immunohistochemical analyses using a 
larger number of thyroid cancer samples are needed 
in order to clarify these results.
   The anti-cell growth activity of dasatinib has been 
studied in various solid tumor cell lines. Based on 
our previous study using six breast cancer cell lines 
consisting of four different breast cancer subtypes 
measured by a similar growth assay to that in the 
present study, the IC50 of dasatinib ranged between 
0.10 μM and 7.5 μM13）. According to a study 
using eight thyroid cancer cell lines including DTC 
and UDTC cell lines reported by Chan CM et al., 
the IC50 of dasatinib ranged between 0.03 μM and 
more than 5 μM５）. These findings suggest that the 
PDTC cell line KTC-1 and UDTC cell line KTC-2 
are more sensitive to dasatinib than the other breast 
cancer and thyroid cancer cell lines.
   The antitumor mechanisms of dasatinib were 
investigated in the present study. In line with 
previous findings from several studies, dasatinib 
dose-dependently induced G1 -S cel l  cycle 
retardation in association with an increase in 
the apoptotic fraction in PDTC and UDTC cell 
lines (Fig. 5). In contrast, paclitaxel induced 
G2-M accumulation in association with increases 
in apoptosis in KTC-2 cells (Fig. 8C, D). The 
combined treatments of dasatinib and paclitaxel 
additively increased the apoptotic fraction measured 
by the cell cycle analysis or Annexin V assay in 
these cell lines (Fig. 8B, D).
   Our previous study and other findings suggest that 
dasatinib exhibits strong anti-CSC activity in breast 
cancer cells15，30）. CSCs have been suggested to 
play a pivotal role in cancer progression, invasion, 
metastasis, and resistance to anticancer agents and 
radiotherapy. Reductions induced in the proportion 
of CSCs in cancer tissues by certain anticancer 
agents may be beneficial for cancer patients to 
achieve the total cell kill of cancer cells or a longer 
remission time. The results of this study clearly 
showed for the first time that dasatinib dose-
dependently decreased the proportion of CSCs 
measured by the Aldefluor assay or thyrosphere 
assay in PDTC KTC-1 cells and UDTC KTC-2 
cells (Fig. 8A-D). In addition, dasatinib constantly 
decreased the proportion of CSCs regardless of the 
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effects of paclitaxel in the combined treatments of 
dasatinib and paclitaxel (Fig. 9A-D). Furthermore, 
combined treatments of dasatinib enhanced the 
antitumor activity of paclitaxel in a more than 
additive manner (Fig. 7A, B). These results suggest 
for the first time that the combined treatment 
of dasatinib and paclitaxel is more beneficial 
for controlling PDTC/UDTC cells than that of 
paclitaxel alone in terms of antitumor activity and 
anti-CSC activity.
   There are some unresolved questions regarding 
the mechanisms responsible for the anti-CSC 
effects of dasatinib in PDTC and UDTC cells. It 
currently remains unclear whether the inhibitory 
effects of dasatinib on the Src signaling pathway 
are the main player regulating the CSC population 
in these thyroid cancer cells.  Dasatinib is a 
multiple tyrosine kinase inhibitor that inhibits the 
following kinases: BCR-ABL, SFKs, c-KIT, ephrin 
type-A receptor, and platelet-derived growth factor 
receptor β. Although the results of our preliminary 
immunohistochemical analysis in this study suggest 
that the Src signaling pathway and its effector 
molecule FAK were up-regulated in PDTC/UDTC 
cells in clinical thyroid cancer samples (Figs. 1, 
2), it is impossible to simply conclude that the Src 
signaling pathway is a main regulator of the CSC 
population in these thyroid cancer cells. In addition, 
a recent study by Thakur R et al. indicated that the 
combined inhibition of STAT3 with Src or FAK 
reduced CSC properties and tumor sphere formation 
more significantly than individual inhibitors in 
breast cancer cells30）. Another study by Luo M et 
al. using a FAK knockout transgenic mouse model 
suggested that FAK plays an important role in the 
maintenance of breast cancer stem/progenitor cells 
and tumorigenicity31）. These findings indicate that 
the inactivation of the signaling pathways of Src 
and FAK plus others by dasatinib regulates the 
proportion of CSCs in thyroid cancer cells.
   In conclusion, the results of the present study 
suggest that the Src signaling pathway is activated 
more in PDTC and UDTC than in DTC. The Src 
inhibitor dasatinib exhibited not only anti-cell 
growth activity, but also anti-CSC activity in the 
PDTC and UDTC cell lines. Furthermore, dasatinib 
more than additively enhanced the anti-cell growth 
activity of paclitaxel in these cell lines. These results 
suggest for the first time that combination therapy 
with dasatinib and paclitaxel has potential in the 
treatment of patients with PDTC and UDTC.
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